Altimmune, Inc.ALTNASDAQ
Loading
Gross Profit Growth AcceleratingAccelerating
Percentile Rank87
3Y CAGR+175.5%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
+175.5%/yr
Quarterly compound
Percentile
P87
Within normal range
vs 3Y Ago
20.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 100.17% |
| Q3 2025 | -299200.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | 104.90% |
| Q1 2024 | -375.68% |
| Q4 2023 | 100.21% |
| Q3 2023 | -36.08% |
| Q2 2023 | -63180.95% |
| Q1 2023 | 100.11% |
| Q4 2022 | 4.79% |
| Q3 2022 | -253350.00% |
| Q2 2022 | 100.05% |
| Q1 2022 | 5.16% |
| Q4 2021 | 38.83% |
| Q3 2021 | -121.15% |
| Q2 2021 | -29.28% |
| Q1 2021 | 19.95% |
| Q4 2020 | -532.03% |
| Q3 2020 | 307.13% |
| Q2 2020 | 122.38% |
| Q1 2020 | -101.89% |
| Q4 2019 | 80.25% |
| Q3 2019 | -512.99% |
| Q2 2019 | -403.31% |
| Q1 2019 | 44.95% |
| Q4 2018 | 77.27% |
| Q3 2018 | 16.29% |
| Q2 2018 | 56.43% |
| Q1 2018 | -247.77% |
| Q4 2017 | -25.69% |
| Q3 2017 | 74.98% |
| Q2 2017 | -164.87% |
| Q1 2017 | -57.67% |
| Q4 2016 | 10.66% |
| Q3 2016 | -292.81% |
| Q2 2016 | 1381.96% |
| Q1 2016 | 79.50% |